Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients

摘要: This multicenter phase II trial evaluated the safety and efficacy of lenalidomide−prednisone (RP) induction, followed by lenalidomide−melphalan−prednisone (MPR) consolidation RP maintenance in elderly unfit newly diagnosed myeloma patients. Patients received four 28-day induction courses (lenalidomide 25 mg/day on days 1–21 prednisone 50 mg three times/week), six MPR cycles (melphalan 2 mg, times/week lenalidomide 10–15 mg/day 1–21), with (10 mg/day every 28 days) plus (25 mg times/week). Forty-six patients were enrolled. Median age was 75 years, 59% had at least one comorbidity 35% two. Partial response rate 80%, including 29% very good partial response. time to progression 19.6 months, median progression-free survival 18.4 months 2-year overall 80%. At tolerated dose 25 mg/month 10 mg/day), most frequent grade 3 adverse events neutropenia (36.4%), anemia (12.1%), cutaneous reactions (18.2%) infections (12.1%). Grade 4 occurred 12.1% In conclusion, showed a manageable profile, reduced risk severe hematological toxicity